TW201827596A - 抑制補體b因子之表現之核酸 - Google Patents

抑制補體b因子之表現之核酸 Download PDF

Info

Publication number
TW201827596A
TW201827596A TW106145253A TW106145253A TW201827596A TW 201827596 A TW201827596 A TW 201827596A TW 106145253 A TW106145253 A TW 106145253A TW 106145253 A TW106145253 A TW 106145253A TW 201827596 A TW201827596 A TW 201827596A
Authority
TW
Taiwan
Prior art keywords
nucleic acid
double
stranded nucleic
nucleotide
stranded
Prior art date
Application number
TW106145253A
Other languages
English (en)
Chinese (zh)
Inventor
山田陽史
清水清
岩井宏徒
Original Assignee
日商協和醱酵麒麟有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商協和醱酵麒麟有限公司 filed Critical 日商協和醱酵麒麟有限公司
Publication of TW201827596A publication Critical patent/TW201827596A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW106145253A 2016-12-23 2017-12-22 抑制補體b因子之表現之核酸 TW201827596A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016250264 2016-12-23
JP2016-250264 2016-12-23

Publications (1)

Publication Number Publication Date
TW201827596A true TW201827596A (zh) 2018-08-01

Family

ID=62626624

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106145253A TW201827596A (zh) 2016-12-23 2017-12-22 抑制補體b因子之表現之核酸

Country Status (2)

Country Link
TW (1) TW201827596A (fr)
WO (1) WO2018117253A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110951915A (zh) * 2019-11-21 2020-04-03 南方医科大学南方医院 一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒
AU2022325715A1 (en) * 2021-07-17 2024-02-01 Sirnaomics, Inc. Products and compositions
CN116769780A (zh) * 2022-07-08 2023-09-19 北京福元医药股份有限公司 用于抑制补体因子B表达的siRNA、其缀合物和药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560931B1 (fr) * 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
EP2943571A4 (fr) * 2013-01-08 2016-11-30 Benitec Biopharma Ltd Traitement de la dégénérescence maculaire liée à l'âge
EP3043827B1 (fr) * 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulateurs du facteur b du complément
CN105814205B (zh) * 2013-12-12 2019-11-19 阿尔尼拉姆医药品有限公司 补体成分iRNA组合物及其使用方法
TW201730341A (zh) * 2016-02-05 2017-09-01 Kyowa Hakko Kirin Co Ltd 抑制補體b因子之表現之反義寡核苷酸

Also Published As

Publication number Publication date
WO2018117253A1 (fr) 2018-06-28

Similar Documents

Publication Publication Date Title
JP6414886B2 (ja) 抗癌治療に用いられる長鎖非コードｒｎａ
JP2010537640A (ja) マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
WO2015137459A1 (fr) Acide nucléique inhibant l'expression d'irf5
TWI718717B (zh) 抑制補體c5表現的雙股核糖核酸
WO2017135397A1 (fr) Oligonucléotide antisens destiné à supprimer l'expression du facteur du complément b
TW201827596A (zh) 抑制補體b因子之表現之核酸
TW201837172A (zh) 抑制masp2之表現之核酸
US20170247701A1 (en) Nucleic acid capable of inhibiting expression of beta-2gpi
US11466272B2 (en) Nucleic acid suppressing expression of APCS
WO2011074652A1 (fr) Acide nucléique capable d'inhiber l'expression de hif-2a
CN114686481B (zh) 一种抑制cfd表达的干扰rna及其制备方法和应用
WO2016021673A1 (fr) Procédé permettant de prédire l'efficacité médicamenteuse d'une composition pharmaceutique contenant un petit arn
TW201713769A (zh) 抑制β２ＧＰＩ之表現之反義寡核苷酸
TW202411424A (zh) 與油酸結合之寡核苷酸及其用途